Welcome to our dedicated page for Gelteq SEC filings (Ticker: GELS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gelteq Limited’s filings often weave clinical trial data, licensing agreements and multi-vertical revenue streams into hundreds of pages of biotech jargon. Finding how much R&D is devoted to its gel-based delivery platform—or spotting when executives buy shares—can feel daunting.
Stock Titan simplifies the search. Our AI reads every Gelteq Limited annual report 10-K, quarterly earnings report 10-Q filing and 8-K material events, then highlights the numbers that matter: segment revenue from pharmaceuticals versus nutraceuticals, new manufacturing commitments and changes in regulatory pathways. Need real-time alerts? Get Gelteq Limited Form 4 insider transactions in seconds, complete with plain-English summaries that explain why an executive moved stock.
Whether you are comparing quarter-over-quarter pipeline costs, monitoring Gelteq Limited proxy statement executive compensation, or just looking for one-page takeaways, you’ll find it here. Use our platform to:
- Track "Gelteq Limited insider trading Form 4 transactions" as they hit EDGAR
- Dive into "understanding Gelteq Limited SEC documents with AI" without parsing legal text
- Receive concise "Gelteq Limited earnings report filing analysis" minutes after posting
All filings, all the time—explained simply, updated instantly and focused on what drives Gelteq Limited’s gel-technology growth.
Golden Matrix Group, Inc. (GMGI) Form 4 filing: Director Thomas E. McChesney reported two open-market stock sales. On 23 June 2025 he sold 5,000 common shares at $1.65; on 24 June 2025 he sold another 5,000 shares at $1.82. Following the transactions, McChesney directly owns 284,710 GMGI shares, remaining a board member and >10% owner status is not indicated. The filing discloses no derivative activity, contracts, or 10b5-1 plans. Investors may view the combined 10,000-share sale as modest (≈3% of his reported stake) but worth monitoring for future insider-trading trends.
FAQ
What is the current stock price of Gelteq (GELS)?
What is the market cap of Gelteq (GELS)?
What is Gelteq Limited's primary area of expertise?
How does Gelteq address challenges in traditional oral delivery methods?
Which market segments does Gelteq serve?
What differentiates Gelteq's business model from traditional drug delivery systems?
Who are the typical customers of Gelteq Limited?
How does Gelteq maintain quality and efficacy in its products?
How does Gelteq compare with competitors in the drug delivery space?
